Regulation of extrathymic T cell development and turnover by oncostatin M

被引:33
作者
Boileau, C
Houde, M
Dulude, G
Clegg, CH
Perreault, C
机构
[1] Hop Maison Neuve Rosemont, Guy Bernier Res Ctr, Montreal, PQ H1T 2M4, Canada
[2] Zymogenet Inc, Seattle, WA 98102 USA
关键词
D O I
10.4049/jimmunol.164.11.5713
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic exposure to oncostatin M (OM) has been shown to stimulate extrathymic T cell development. The present work shows that in OM transgenic mice, 1) massive extrathymic T cell development takes place exclusively the lymph nodes (LNs) and not in the bone marrow, liver, intestines, or spleen; and 2) LNs are the sole site where the size of the mature CD4(+) and CD8(+) T cell pool is increased (6- to 7-fold). Moreover, when injected into OM transgenic mice, both transgenic and nontransgenic CD4(+) and CD8(+) T cells preferentially migrated to the LNs rather than the spleen. Studies of athymic recipients of fetal liver grafts showed that lymphopoietic pathway modulated by OM was truly thymus independent, and that nontransgenic progenitors could generate extrathymic CD4(+)CD8(+) cells as well as mature T cells under the paracrine influence of OM, The progeny of the thymic-independent differentiation pathway regulated by OM was polyclonal in terms of V beta usage, exhibited a phenotype associated with previous TCR ligation, and displayed a rapid turnover rate (5-bromo-2'-deoxyuridine pulse-chase assays). This work suggests that chronic exposure to OM 1) discloses a unique ability of LNs to sustain extrathymic T cell development, and 2) increases the number and/or function of LN niches able to support seeding of recirculating mature T cells. Regulation of the lymphopoietic pathway discovered in OM transgenic mice could be of therapeutic interest for individuals with thymic hypoplasia or deficient peripheral T cell niches.
引用
收藏
页码:5713 / 5720
页数:8
相关论文
共 82 条
  • [31] LEUKOCYTE MIGRATION AND ADHESION
    IMHOF, BA
    DUNON, D
    [J]. ADVANCES IN IMMUNOLOGY, VOL 58, 1995, 58 : 345 - 416
  • [32] JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521
  • [33] Kishimoto H, 1999, J IMMUNOL, V163, P1817
  • [34] OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
    Kong, YY
    Yoshida, H
    Sarosi, I
    Tan, HL
    Timms, E
    Capparelli, C
    Morony, S
    Oliveira-dos-Santos, AJ
    Van, G
    Itie, A
    Khoo, W
    Wakeham, A
    Dunstan, CR
    Lacey, DL
    Mak, TW
    Boyle, WJ
    Penninger, JM
    [J]. NATURE, 1999, 397 (6717) : 315 - 323
  • [35] B-CELL STIMULATING FACTOR-2/INTERLEUKIN-6 IS A COSTIMULANT FOR HUMAN THYMOCYTES AND LYMPHOCYTES-T
    LOTZ, M
    JIRIK, F
    KABOURIDIS, P
    TSOUKAS, C
    HIRANO, T
    KISHIMOTO, T
    CARSON, DA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (03) : 1253 - 1258
  • [36] Oncostatin M: Development of a pleiotropic cytokine
    Loy, JK
    Davidson, TJ
    Berry, KK
    Macmaster, JF
    Danle, B
    Durham, SK
    [J]. TOXICOLOGIC PATHOLOGY, 1999, 27 (02) : 151 - 155
  • [37] AGE, THYMOPOIESIS, AND CD4+ T-LYMPHOCYTE REGENERATION AFTER INTENSIVE CHEMOTHERAPY
    MACKALL, CL
    FLEISHER, TA
    BROWN, MR
    ANDRICH, MP
    CHEN, CC
    FEUERSTEIN, IM
    HOROWITZ, ME
    MAGRATH, IT
    SHAD, AT
    STEINBERG, SM
    WEXLER, LH
    GRESS, RE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (03) : 143 - 149
  • [38] MACKALL CL, 1994, BLOOD, V84, P2221
  • [39] Distinctions between CD8(+) and CD4(+) T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy
    Mackall, CL
    Fleisher, TA
    Brown, MR
    Andrich, MP
    Chen, CC
    Feuerstein, IM
    Magrath, IT
    Wexler, LH
    Dimitrov, DS
    Gress, RE
    [J]. BLOOD, 1997, 89 (10) : 3700 - 3707
  • [40] T-cell regeneration: All repertoires are not created equal
    Mackall, CL
    Hakim, FT
    Gress, RE
    [J]. IMMUNOLOGY TODAY, 1997, 18 (05): : 245 - 251